Allogeneic Hematopoietic Cell Transplantation for Congenital Athymia: A Nationwide Retrospective Study in Japan

Read full text Summarise with VIRAT
Authors: Tsubasa Nishinosono, Hideki Muramatsu, Manabu Wakamatsu, Motoshi Sonoda, Katsuhide Eguchi, Koji Kawaguchi, Takeshi Yamamoto, Takahiro Kudo, Michiko Kajiwara, Masataka Ishimura, Yoshiyuki Takahashi
Cited by: 0
References: 33

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Purpose Congenital athymia is a life-threatening condition characterized by thymic absence and profound T-cell immunodeficiency. Thymus implantation is the definitive treatment, but its availability is limited. This study aimed to evaluate the outcomes of hematopoietic cell transplantation (HCT) as an alternative therapy. Methods A nationwide, multicenter, retrospective study analyzed nine patients who underwent allogeneic HCT between 2000 and 2024 in Japan. Overall survival (OS) was estimated using the Kaplan–Meier method, and the cumulative incidence of immunodeficiency-related mortality was assessed using Gray’s test. Results Among the nine patients, eight (89%) received umbilical cord blood, and one (11%) received related peripheral blood. Seven patients (78%) underwent transplantation without conditioning. Engraftment with T-cell recovery was achieved in six patients (67%), with a median CD4 + T-cell count of 0.352 × 10 9 /L (range, 0.216–1.578 × 10 9 /L) at the last follow-up. Acute graft-versus-host disease (GVHD) occurred in five patients (56%), all with Grade I–II skin involvement. No chronic GVHD was observed. The one-year OS rate was 66.7% (95% confidence interval: 28.2%–87.8%). Overall, six patients (67%) died: three early deaths within the first month from infections, and three late deaths beyond 1 year from congenital comorbidities. HCT before six months of age was associated with significantly lower immunodeficiency-related mortality ( p = 0.02). Conclusion HCT can allow immune reconstitution in congenital athymia, although long-term survival is affected by comorbidities. Early diagnosis and timely intervention are crucial in managing this condition. HCT can be a restricted alternative therapy for patients ineligible for thymus implantation.

Fields of Study & Subjects

Immunodeficiency and Autoimmune Disorders Hematopoietic Stem Cell Transplantation Transplantation: Methods and Outcomes

Publication details

Journal / source
Journal of Clinical Immunology
Volume
46
Issue
1
Publication date
28 March 2026
Language
EN